Home › Multiple Sclerosis › North Carolina › Charlotte
Multiple Sclerosis clinical trials in Charlotte, NC
3 studies for Multiple Sclerosis are looking for participants at sites in and around Charlotte (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
RecruitingObservational study
- TG Therapeutics Investigational Trial Site, Charlotte
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
RecruitingPhase 3
- Piedmont HealthCare - Lake Norman Neurology- Site Number : 8400002, Charlotte
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
RecruitingPhase 3
- Atrium Health, Charlotte
About Multiple Sclerosis
Multiple sclerosis (MS) slows down or blocks messages between the brain and body. MS can be mild or severe. Learn about MS symptoms and treatment.
More about Multiple Sclerosis on MedlinePlus
Multiple Sclerosis trials in other cities
- New York City, NY17 studies
- Chicago, IL15 studies
- Boston, MA14 studies
- Washington, DC13 studies
- Cleveland, OH10 studies
- Birmingham, AL9 studies
- Aurora, CO8 studies
- Kansas City, KS8 studies
- St. Louis, MO8 studies
- San Francisco, CA8 studies
- Tampa, FL7 studies
- Dallas, TX7 studies
Other studies in Charlotte
- Cancer (all types)29 studies
- Breast Cancer22 studies
- Non-Small Cell Lung Cancer22 studies
- Multiple Myeloma21 studies
- Acute Myeloid Leukemia18 studies
- Ovarian Cancer16 studies
- Obesity16 studies
- Colorectal Cancer15 studies
- Overweight15 studies
- Metastatic Cancer12 studies
- Heart Failure12 studies
- Head and Neck Squamous Cell Carcinoma11 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.